stockrow
Saturday 7 November 2026
Export ELTX’s income statement to Excel — free account
Elicio Therapeutics, Inc.
ELTX Healthcare Biotechnology
- EPS
- +34.9%
- Free cash flow
- +8.77%
- Total debt
- +2.12%
Quarter to June 2026, against a year earlier
1.52
0.12
+8.57%
Follow ELTX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | 4 | 1 | 3 | 28 | — | — | — | — | 29 | +91.5% | — | — | — | — | |
| Gross margin, % | — | — | 90.62 | 56.96 | 58.68 | 98.47 | 100.00 | — | — | — | 0.00 | +9.4 pt | ||||||
| EBT | — | — | (20) | (41) | (80) | (55) | (28) | (35) | (52) | (40) | (38) | +10.2% | ||||||
| EBT margin, % | — | — | (497.02) | (2,734.23) | (2,781.49) | (192.76) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +497.0 pt | ||||||
| Net income | — | 0 | (20) | (41) | (80) | (55) | (28) | (35) | (52) | (40) | (38) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 1.37 | 1.03 | 1.95 | 10.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (8.48) | (28.17) | (54.30) | (19.30) | (89.27) | (6.96) | (4.25) | (2.58) | (2.17) | (15.6%) | ||||||
| Cash flow | — | — | (2.72) | (17.03) | (15.50) | (18.64) | (70.19) | (6.47) | (3.04) | (2.41) | (1.96) | (1.7%) | ||||||
| Capex | — | — | 0.00 | (0.17) | (0.03) | (0.14) | (2.07) | (0.01) | (0.01) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | (2.72) | (17.20) | (15.53) | (18.77) | (72.26) | (6.47) | (3.04) | (2.41) | (1.96) | (1.7%) | ||||||
| Book value | — | — | 6.42 | (12.88) | (61.27) | 28.86 | 28.21 | 2.25 | (0.93) | 0.11 | 0.41 | (44.3%) | ||||||
| Shares, m | — | — | 3 | 1 | 1 | 3 | 0 | 5 | 12 | 15 | 17 | +26.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 | |||||
| P/S | — | — | 89.87 | 89.87 | 89.87 | 2.89 | 0.10 | — | — | — | 1.01 | 54.5 | ||||||
| P/B | — | — | 0.00 | 0.00 | 0.00 | 1.01 | 0.00 | — | — | — | 3.69 | 0.2 | ||||||
| EV/Sales | — | — | 78.16 | 78.16 | 78.16 | (0.20) | (0.05) | — | — | — | 0.56 | 46.8 | ||||||
| EV/FCF | — | — | (9.82) | (9.82) | (9.82) | 0.11 | 0.06 | — | — | — | (0.43) | (5.9) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (8) | (25) | (23) | (53) | (22) | (33) | (37) | (37) | (38) | +24.4% | |||||
| Capex | — | — | — | 0 | 0 | 0 | (1) | 0 | 0 | 0 | 0 | (36.4%) | ||||||
| Free cash flow | — | — | (8) | (25) | (23) | (53) | (23) | (33) | (37) | (37) | (38) | +24.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 18 | (20) | (65) | 80 | 4 | 7 | 9 | 11 | 16 | (6.8%) | |||||
| Net debt | — | — | (26) | 5 | (34) | (89) | (8) | (14) | 1 | (9) | (14) | (13.6%) | ||||||
| Shareholders’ equity | — | — | 19 | (19) | (90) | 82 | 9 | 11 | (11) | 2 | 8 | (29.5%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (187.81) | (211.13) | (270.48) | (75.87) | (47.34) | (141.32) | (187.61) | (146.45) | (124.36) | +41.4 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (1,153.43) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | (15,387.69) | (25,020.31) | 146.94 | 1,220.60 | 273.36 | 77.55 | (170,157.38) | 817.92 | (774.56) | +16,205.6 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 53 | 71 | 12 | 32 | 32 | 33 | — | (9.0%) | |||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.05 | 0.40 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2021 · latest quarter Mar 2022 · fundamentals updated 26 Oct 2026
Elicio Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| HYPD Hyperion DeFi, Inc. | $39.8M | — (loss-making) | 0.5× | +2,333.33% (above 0%: growing) | n/m | +86.82% (above 0%: growing) | 100.00% | 8,668.63% | Compare |
| DWTX Dogwood Therapeutics, Inc | $39.8M | — (loss-making) | — | — | n/m | +10.31% (above 0%: growing) | — | 0.00% | Compare |
| EXOZ eXoZymes Inc. | $38.1M | — (loss-making) | — | — | n/m | −3.25% (below 0%: shrinking) | — | 0.00% | Compare |
| IBO Impact Biomedical Inc. | $38.0M | — (loss-making) | — | −57.14% (below 0%: shrinking) | n/m | +167.72% (above 0%: growing) | 66.67% | (23,400.00%) | Compare |
| ELTX Elicio Therapeutics, Inc. | $37.9M | — (loss-making) | — (loss-making) | −55.27% (below 0%: shrinking) | n/m | +8.77% (above 0%: growing) | 0.00% | 0.00% | |
| GRCE Grace Therapeutics, Inc. | $37.5M | — (loss-making) | — (loss-making) | +5,127.27% (above 0%: growing) | n/m | −78.85% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALDX Aldeyra Therapeutics, Inc. | $37.2M | — (loss-making) | — | — | n/m | +46.09% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TVGN Tevogen Inc. | $36.2M | — (loss-making) | — | — | n/m | +5.78% (above 0%: growing) | — | 0.00% | Compare |
| PTHS Pelthos Therapeutics Inc. | $35.6M | — (loss-making) | — (loss-making) | — | n/m | −1,614.99% (below 0%: shrinking) | 76.86% | (111.02%) | Compare |
| Median of peers | $37.7M | — | — | +2,333.33% | — | +8.05% | 66.67% | 0.00% |
Pay and ownership Proxy statement filed 9 October 2026
Ownership
Directors and executive officers, together
34.60%
Yekaterina (Katie) Chudnovsky
31.10%
GKCC, LLC
23.20%
Moti Investments LLC
5.20%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement